diaziquone has been researched along with mitoxantrone in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (30.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Amrein, PC; Davis, RB; Mayer, RJ; Schiffer, CA | 1 |
| Camacho, FJ; Chang, AY; Ettinger, DS; Finkelstein, DM; Harper, GR; Marsh, JC; Ruckdeschel, JC; Silber, R; Wolter, JM | 1 |
| Ogawa, M | 1 |
| Amrein, PC; Dodge, RK; Godfrey, S; Kolitz, J; Lee, EJ; Moore, JO; Powell, B; Robert, F; Schiffer, CA | 1 |
| Allen, SL; Amrein, PC; George, SL; Lee, EJ; Paciucci, PA; Schiffer, CA | 1 |
| Baer, MR; Block, AW; Bloomfield, CD; Carroll, AJ; Farag, SS; Koduru, PR; Kolitz, JE; Larson, RA; Mayer, RJ; Moore, JO; Mrózek, K; Pettenati, MJ; Powell, BL; Ruppert, AS; Schiffer, CA; Stamberg, J; Stone, RM; Vardiman, JW | 1 |
| Baylouny, RA; Bissell, EC; Holiat, SM; Hubert, DD; Smith, WE; Sobel, HJ; Watts, LM; Yazdi, E | 1 |
| Bloomfield, CD; Carroll, AJ; Edwards, CG; Kolitz, JE; Larson, RA; Maharry, K; Marcucci, G; Mayer, RJ; Moore, JO; Mrózek, K; Pettenati, MJ; Powell, BL; Ruppert, AS; Schiffer, CA; Sterling, LJ; Vardiman, JW | 1 |
1 review(s) available for diaziquone and mitoxantrone
| Article | Year |
|---|---|
[Current status of clinical results of new antitumor drugs].
Topics: Aminoacridines; Amsacrine; Anthracyclines; Anthraquinones; Antibiotics, Antineoplastic; Antineoplastic Agents; Aziridines; Benzoquinones; Carboplatin; Carubicin; Cisplatin; Daunorubicin; Doxorubicin; Eflornithine; Epirubicin; Humans; Idarubicin; Mitoxantrone; Naphthacenes; Neoplasms; Organoplatinum Compounds; Ornithine; Ribavirin | 1985 |
4 trial(s) available for diaziquone and mitoxantrone
| Article | Year |
|---|---|
Phase II study of mitoxantrone, aclarubicin, and diaziquone in the treatment of non-small cell lung carcinoma: an Eastern Cooperative Oncology Group study.
Topics: Aclarubicin; Aged; Anaphylaxis; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Drug Evaluation; Female; Hematologic Diseases; Humans; Infusions, Parenteral; Lung Neoplasms; Male; Middle Aged; Mitoxantrone; Naphthacenes | 1985 |
Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Bone Marrow; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Granulocytes; Humans; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Mitoxantrone; Pilot Projects; Platelet Count; Recombinant Proteins; Remission Induction | 1997 |
An evaluation of combinations of diaziquone, etoposide and mitoxantrone in the treatment of adults with relapsed or refractory acute myeloid leukemia: results of 8722, a randomized phase II study conducted by Cancer and Leukemia Group B.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone | 1998 |
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Recurrence; Splenomegaly; Survival Analysis; Treatment Outcome | 2005 |
5 other study(ies) available for diaziquone and mitoxantrone
| Article | Year |
|---|---|
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Treatment of relapsed and refractory acute myeloid leukemia with diaziquone and mitoxantrone: a CALGB phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Remission Induction; Survival Analysis; Time Factors | 1990 |
Twenty-first Paterson symposium: bioactivation of quinone anti-tumor agents.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Aziridines; Benzoquinones; Biotransformation; DNA Damage; Free Radicals; Mitomycin; Mitomycins; Mitoxantrone; Naphthacenes; Quinones | 1987 |
Complete remissions in chemotherapy of lung cancer models induced in mice by asbestos.
Topics: Animals; Antineoplastic Agents; Asbestos, Serpentine; Aziridines; Benzoquinones; Carcinoma, Squamous Cell; Cisplatin; Dianhydrogalactitol; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mitoxantrone; Models, Animal; Nitrosourea Compounds; Pentostatin; Remission Induction; Survival Analysis; Triazines | 2005 |
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Chromosome Aberrations; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Proportional Hazards Models; Prospective Studies; Remission Induction; Statistics, Nonparametric; Survival Analysis | 2005 |